Baseline demographics and clinical characteristics | Adherence assessment population | Persistence assessment population | ||||
---|---|---|---|---|---|---|
Overall patients (N = 1744) | STRs (N = 1290) | MTRs (N = 454) | Overall patients (N = 2409) | STRs (N = 1782) | MTRs (N = 627) | |
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Mean age (mean ± SD) | 41.0 ± 12.9 | 40.0 ± 13.3 | 42.0 ± 11.8 | 40.1 ± 13.1 | 40.0 ± 13.5 | 41.0 ± 12.0 |
Age group (years) | ||||||
 18–34 | 631 (36.2%) | 493 (38.2%) | 138 (30.4%) | 918 (38.1%) | 714 (40.1%) | 204 (32.5%) |
 35–49 | 614 (35.2%) | 432 (33.5%) | 182 (40.1%) | 805 (33.4%) | 559 (31.4%) | 246 (39.2%) |
 50–64 | 468 (26.8%) | 338 (26.2%) | 130 (26.8%) | 646 (26.8%) | 473 (26.5%) | 173 (27.6%) |
 ≥ 65 | 31 (1.8%) | 27 (2.1%) | 4 (0.9%) | 40 (1.7%) | 36 (2.0%) | 4 (0.6%) |
Gender | ||||||
 Male | 986 (56.5%) | 741 (57.4%) | 245 (54.0%) | 1353 (56.2%) | 1026 (57.6%) | 327 (52.2%) |
 Female | 758 (43.5%) | 549 (42.6%) | 209 (46.0%) | 1056 (43.8%) | 756 (42.4%) | 300 (47.8%) |
Race | ||||||
 White | 350 (20.1%) | 270 (20.9%) | 80 (17.6%) | 472 (19.6%) | 358 (20.1%) | 114 (18.2%) |
 Black | 1064 (61.0%) | 779 (60.4%) | 285 (62.8%) | 1460 (60.6%) | 1078 (60.5%) | 382 (60.9%) |
 Hispanic | 26 (1.5%) | 18 (1.4%) | 8 (1.8%) | 37 (1.6%) | 26 (1.5%) | 11 (1.8%) |
 Other | 304 (17.4%) | 223 (17.3%) | 81 (17.8%) | 440 (18.3%) | 320 (18.0%) | 120 (19.1%) |
Insurance type | ||||||
 HMO | 445 (25.5%) | 342 (26.5%) | 103 (22.7%) | 635 (26.4%) | 480 (26.9%) | 155 (24.7%) |
 COMP | 1298 (74.4%) | 948 (73.5%) | 350 (77.1%) | 1773 (73.6%) | 1302 (73.1%) | 471 (75.1%) |
Pre-index medication use | ||||||
 Antihypertensive | 439 (25.2%) | 329 (25.5%) | 110 (24.2%) | 567 (23.5%) | 425 (23.8%) | 142 (22.6%) |
 Antidiabetics | 106 (6.1%) | 83 (6.4%) | 23 (5.1%) | 143 (5.9%) | 107 (6.0%) | 36 (5.7%) |
 Metformin | 67 (3.8%) | 54 (4.2%) | 13 (2.9%) | 86 (3.6%) | 68 (3.8%) | 18 (2.9%) |
 Metformin-combination | 4 (0.2%) | 3 (0.2%) | 1 (0.2%) | 5 (0.2%) | 3 (0.2%) | 2 (0.3%) |
 Non-insulin therapy | 78 (4.5%) | 63 (4.9%) | 15 (3.3%) | 101 (4.2%) | 80 (4.5%) | 21 (3.3%) |
 Insulin | 43 (2.5%) | 32 (2.5%) | 11 (2.4%) | 59 (2.5%) | 43 (2.4%) | 16 (2.6%) |
 Anticoagulants | 102 (5.9%) | 77 (6.0%) | 25 (5.5%) | 133 (5.5%) | 101 (5.7%) | 32 (5.1%) |
 Antiarrhythmic drugs | 1 (0.1%) | 1 (0.1%) | 0 (0.0%) | 1 (0.04%) | 1 (0.1%) | 0 (0.0%) |
 Lipid-lowering therapy | 150 (8.6%) | 111 (8.6%) | 39 (8.6%) | 193 (8.0%) | 143 (8.0%) | 50 (8.0%) |
 Statin | 148 (8.5%) | 110 (8.5%) | 38 (8.4%) | 191 (7.9%) | 142 (8.0%) | 49 (7.8%) |
 Ezetimibe | 3 (0.2%) | 2 (0.2%) | 1 (0.2%) | 3 (0.1%) | 2 (0.1%) | 1 (0.2%) |
 Statin/ezetimibe | 1 (0.1%) | 1 (0.1%) | 0 (0.0%) | 1 (0.04%) | 1 (0.1%) | 0 (0.0%) |
 PCSK9 |  | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.0%) |
 Antibiotics | 759 (43.5%) | 584 (45.3%) | 175 (38.5%) | 1068 (44.3%) | 810 (45.5%) | 258 (41.1%) |
 Respiratory drugsa | 958 (54.9%) | 735 (57.0%) | 223 (49.1%) | 1353 (56.2%) | 1029 (57.7%) | 324 (51.7%) |
 Number of unique medications on index date besides ART (mean ± SD) | 1.0 ± 1.9 | 0.9 ± 1.8 | 1.3 ± 2.1 | 1.0 ± 2.0 | 1.0 ± 1.9 | 1.3 ± 2.3 |
 Deyo-modified CCI score (mean ± SD) | 4.2 ± 3.4 | 4.1 ± 3.4 | 4.4 ± 3.4 | 3.4 ± 3.5 | 3.4 ± 3.5 | 3.6 ± 3.5 |
Baseline clinical comorbidities | ||||||
 Central nervous system toxicity | 714 (40.9%) | 530 (41.1%) | 184 (40.5%) | 811 (33.7%) | 598 (33.6%) | 213 (34.0%) |
 Gastrointestinal symptoms | 74 (4.2%) | 55 (4.3%) | 19 (4.2%) | 81 (3.7%) | 60 (3.4%) | 21 (3.3%) |
 Mental disorders | 986 (56.5%) | 732 (56.7%) | 254 (55.9%) | 1134 (47.1%) | 835 (46.9%) | 299 (47.7%) |
 AIDS-defining condition | 118 (6.8%) | 79 (6.1%) | 39 (8.6%) | 124 (5.2%) | 82 (4.6%) | 42 (6.7%) |
 Substance abuse | 724 (41.5%) | 522 (40.5%) | 202 (44.5%) | 827 (34.3%) | 591 (33.2%) | 236 (37.6%) |
 Jaundice | 9 (0.5%) | 6 (0.5%) | 3 (0.7%) | 9 (0.4%) | 6 (0.3%) | 3 (0.5%) |
 Dyslipidemia | 251 (14.4%) | 193 (15.0%) | 58 (12.8%) | 270 (11.2%) | 209 (11.7%) | 61 (9.7%) |
 Diabetes | 149 (8.5%) | 115 (8.9%) | 34 (7.5%) | 172 (7.1%) | 131 (7.4%) | 41 (6.5%) |
 Chronic kidney disease | 58 (3.3%) | 42 (3.3%) | 16 (3.5%) | 62 (2.6%) | 46 (2.6%) | 16 (2.6%) |
 Cardiovascular disease | 562 (32.2%) | 415 (32.2%) | 147 (32.4%) | 628 (26.1%) | 465 (26.1%) | 163 (26.0%) |
 Myocardial infarction | 12 (0.7%) | 8 (0.6%) | 4 (0.9%) | 12 (0.5%) | 8 (0.4%) | 4 (0.6%) |